Why Biotechs Choose Australia for First-in-Human Trials

Tina Soulis details Australia’s advantages for early-stage trials, including tax incentives, no IND requirement, and flexibility in trial design. She describes the typical biotech client profile and explains how adaptive trials are increasingly common. Tina also highlights that Australian-generated data is accepted by global regulators, strengthening biotech strategies.